Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add‐on to metformin in type 2 diabetes with mild hyperglycaemia

Empagliflozin led to reductions in HbA1c ranging from -0.09 to -0.56% after 12 weeks in patients with type 2 diabetes inadequately controlled on metformin.

• Compared to placebo, empagliflozin doses of 5 to 50 mg resulted in reductions in fasting plasma glucose from -2 to -28 mg/dl.
• Body weight decreased by -2.3 to -2.9 kg with empagliflozin, while the placebo group experienced a decrease of -1.2 kg.
• The frequency of adverse events was generally similar across empagliflozin (29.6-48.6%), placebo (36.6%), and sitagliptin (35.2%).
• Hypoglycemia rates were very low and balanced among all treatment groups.
• The most common adverse events with empagliflozin included urinary tract infections (4.0%) and pollakiuria (2.5%), with genital infections occurring only in the empagliflozin group (4.0%).

AI simplified